Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group.

@article{Rssner2000WeightLW,
  title={Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group.},
  author={Stephan R{\"o}ssner and Lars Sj{\"o}str{\"o}m and Rudolf Noack and Arend E. Meinders and Giorgio Noseda},
  journal={Obesity research},
  year={2000},
  volume={8 1},
  pages={
          49-61
        }
}
OBJECTIVE To determine the effect of orlistat, a new lipase inhibitor, on long-term weight loss, to determine the extent to which orlistat treatment minimizes weight regain in a second year of treatment, and to assess the effects of orlistat on obesity-related risk factors. RESEARCH METHODS AND PROCEDURES This was a 2-year, multicenter, randomized, double-blind, placebo-controlled study. Obese patients (body mass index 28 to 43 kg/m2) were randomized to placebo or orlistat (60 or 120 mg… Expand
Effect of Orlistat on Weight Regain and Cardiovascular Risk Factors Following a Very-Low-Energy Diet in Abdominally Obese Patients
TLDR
The addition of orlistat to lifestyle intervention was associated with maintenance of an extra 2.4 kg weight loss after VLED for up to 3 years in obese subjects and the combination oforlistat and lifestyle interventionwas associated with a reduced occurrence of type 2 diabetes. Expand
Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity
TLDR
A clinically meaningful reduction in body weight and the maintenance of this weight loss is achievable with orlistat treatment and dietary restriction over a period of 18 months, and resulted in an improvement in risk factors for coronary heart disease. Expand
Predictive value of early weight loss in obesity management with orlistat: an evidence-based assessment of prescribing guidelines
TLDR
Of the criteria currently suggested for assessing response to orlistat treatment, weight loss of ≥5% at 12 weeks accurately predicts sustained improvements in weight and major risk factors at 2 years, while other suggested criteria are less useful. Expand
The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without type 2 diabetes.
TLDR
Short-term orlistat treatment without the use of a hypocaloric diet significantly improved insulin sensitivity and cardiovascular risk profiles in severely obese Chinese patients with or without type 2 diabetes mellitus. Expand
Weight Loss and Quality of Life Improvement in Obese Subjects Treated with Sibutramine: A Double-Blind Randomized Multicenter Study
TLDR
It is confirmed that sibutramine significantly enhances the effect of diet on weight loss, BMI and waist circumference reduction, and showed a significant improvement of QoL. Expand
Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension
TLDR
Orlistat promotes clinically meaningful weight loss that is associated with significant reductions in blood pressure and heart rate, and may therefore have a role in the management of hypertension in overweight and obese patients. Expand
Obesity: Low-Dose Orlistat Effects on Body Weight of Mildly to Moderately Overweight Individuals: A 16 Week, Double-Blind, Placebo-Controlled Trial
TLDR
The use of orlistat 60 mg by mildly to moderately overweight individuals produced significant weight loss in conjunction with a reduced calorie diet and self-instructional materials and has the potential to contribute significantly to weight and risk factor improvement for overweight individuals. Expand
Long-term (2-4 year) weight reduction with metformin plus carbohydrate-modified diet in euglycemic, hyperinsulinemic, midlife women (Syndrome W).
TLDR
It is suggested that metformin may be an effective long-term adjunct to dietary and other interventions in the treatment of obesity in hyperinsulinemic patients and a randomized clinical trial of the dual regimen should be considered in nondiabetic women with midlife weight gain and hyperinsulinemia. Expand
Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet : a systematic review of randomized clinical trials 1 , 2
Background: Obesity is a growing health concern in Canada and the United States, and pharmacologic therapies such as orlistat are being more commonly prescribed to assist with weight loss. Objective:Expand
Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials.
TLDR
The findings suggest that 3 x 120 mg orlistat/d is effective for improving both weight loss and serum lipid profiles in overweight patients at low and high cardiovascular disease risk and in obese patients with type 2 diabetes. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 33 REFERENCES
Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients
TLDR
Orlistat taken with an appropriate diet promotes clinically significant weight loss and reduces weight regain in obese patients over a 2 year period and the use of orlistat beyond 2 years needs careful monitoring with respect to efficacy and adverse events. Expand
Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study
TLDR
Weight-reducing efficacy of orlistat, a novel gastrointestinal lipase inhibitor, and to define the optimal dosage regimen and establish the tolerability of the drug when used for a 6-month treatment period are determined. Expand
Long-term changes of body weight and cardiovascular risk factors after weight reduction with group therapy and dexfenfluramine.
The aim of this work was to investigate the long-term changes of body weight and cardiovascular risk factors after weight reduction with dexfenfluramine (dF) compared to placebo (pI) and additionalExpand
Beneficial health effects of modest weight loss
TLDR
In conclusion, a large proportion of obese individuals with NIDDM, hypertension, and hyperlipidemia experienced positive health benefits with modest weight loss, and even a small amount of weight loss appears to benefit a substantial subset of obese patients. Expand
Beneficial health effects of modest weight loss.
  • D. Goldstein
  • Medicine
  • International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity
  • 1992
TLDR
In conclusion, a large proportion of obese individuals with NIDDM, hypertension, and hyperlipidemia experienced positive health benefits with modest weight loss, and even a small amount of weight loss appears to benefit a substantial subset of obese patients. Expand
Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study.
  • M. Drent, I. Larsson, +6 authors E. A. van der Veen
  • Medicine
  • International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity
  • 1995
TLDR
Orlistat, in an apparently dose-dependent manner, leads to additional weight loss compared to diet alone and overall, is well tolerated. Expand
Comparison of 2-year weight loss trends in behavioral treatments of obesity: diet, exercise, and combination interventions.
TLDR
The results suggest that dieting is associated with weight loss followed by regain after treatment ends, whereas exercise alone produced smaller weight losses but better maintenance. Expand
Evidence for Success of Caloric Restriction in Weight Loss and Control: Summary of Data from Industry
TLDR
Evaluating industry's supporting evidence for the success of weight-loss programs found some combination of reduced-calorie meals or meal replacements, education, behavior modification, individual or group counseling, and aerobic exercise to be safe and effective. Expand
Lipase inhibition: a novel concept in the treatment of obesity.
  • M. Drent, E. A. van der Veen
  • Medicine
  • International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity
  • 1993
Orlistat (Ro 18-0647) is an inhibitor of gastric, carboxylester and pancreatic lipase and specifically reduces the absorption of dietary fat due to the inhibition of triglyceride hydrolysis. OrlistatExpand
The beneficial effects of modest weight loss on cardiovascular risk factors.
TLDR
Despite the limited success of long-term weight reduction programmes, it seems worthwhile to motivate overweight people to attempt even a modest amount of weight loss, since this may help to reduce cardiovascular risk factors and total mortality. Expand
...
1
2
3
4
...